Cervical Vertebral Stenotic Myelopathy (CVSM)

Cervical Vertebral Stenotic Myelopathy (CVSM), commonly known as Wobbler Syndrome, is a progressive, multifactorial neurological disorder of horses characterized by compression of the cervical spinal cord due to stenosis (narrowing) of the vertebral canal. This compression results in ataxia, paresis, and proprioceptive deficits, primarily affecting the hindlimbs, and can also cause neck pain and abnormal gait. CVSM is a leading cause of neurological disease in young, rapidly growing horses, particularly Thoroughbreds and Warmbloods, and can also affect adult horses. The condition is classified into two main types: Type I (cervical vertebral malformation) and Type II (cervical vertebral instability or 'wobbles'), with Type I further subdivided into Type I-A (stenosis due to malformed vertebrae) and Type I-B (stenosis due to articular process hypertrophy). The disease imposes significant economic and welfare burdens on the equine industry due to loss of athletic potential, diagnostic costs, and humane euthanasia in severe cases.

The exact etiology of CVSM is multifactorial, involving genetic predisposition, nutritional factors, biomechanical stress, and possibly trauma. Primary causative factors include: (1) Genetic susceptibility: Certain breeds, especially Thoroughbreds and Warmbloods, have a higher prevalence, suggesting a heritable component. (2) Nutritional imbalances: Excessive energy intake, particularly high-concentrate diets, and imbalances in calcium, phosphorus, copper, and zinc have been implicated in abnormal bone development and osteochondrosis. (3) Rapid growth: Fast growth rates in young horses may lead to vertebral malformation and articular process hypertrophy. (4) Biomechanical stress: Repetitive flexion and extension of the neck during exercise or restraint may exacerbate instability and compression. (5) Trauma: Acute injury to the cervical spine can cause vertebral fracture or subluxation, leading to stenosis. (6) Osteochondrosis: Lesions in the articular processes or vertebral endplates can contribute to malformation and stenosis. (7) Inflammatory or infectious processes: Rarely, osteomyelitis or diskospondylitis may cause vertebral canal stenosis. (8) Metabolic diseases: Conditions like equine metabolic syndrome may influence bone and cartilage development.

CVSM predominantly affects young, rapidly growing horses, typically between 6 months and 4 years of age, with a peak incidence around 1-2 years. Thoroughbreds, Warmbloods, and other large breeds are overrepresented, while Quarter Horses and Arabians are less commonly affected. Males may be slightly more predisposed than females. The condition is more common in horses raised in confinement with high-concentrate diets and limited pasture access. The prevalence in Thoroughbred racehorses has been reported as 1-2% of all horses, but among horses presented for neurological evaluation, it may account for up to 20-30% of cases. Morbidity is significant, as affected horses often require retirement from athletic careers. Mortality is low unless euthanasia is elected due to severe neurological deficits or poor prognosis. The economic impact includes diagnostic costs, loss of training and competition, and potential breeding losses.

The pathophysiology of CVSM involves compression of the cervical spinal cord due to vertebral canal stenosis. This stenosis can result from: (1) Malformation of the vertebral bodies, leading to a reduced sagittal diameter of the canal. (2) Hypertrophy of the articular processes (synovial joints) that impinge on the dorsal aspect of the spinal cord. (3) Instability between adjacent vertebrae, causing dynamic compression during neck movement. (4) Dorsal displacement of the vertebral arch or ligamentum flavum hypertrophy. The compression leads to direct mechanical injury to the spinal cord, causing demyelination, axonal degeneration, and neuronal loss. Additionally, vascular compromise may result in ischemia and edema. The clinical signs reflect upper motor neuron (UMN) and general proprioceptive (GP) pathway dysfunction, leading to ataxia, weakness, and incoordination, particularly in the hindlimbs. In severe cases, compression of the lower motor neurons (LMN) in the cervical intumescence can cause forelimb paresis and muscle atrophy.

Intrinsic factors include: (1) Genetic predisposition: Certain bloodlines within breeds have higher incidence. (2) Age: Young, growing horses are at highest risk. (3) Sex: Males may be slightly more predisposed. (4) Conformation: Long, thin necks may be more susceptible. (5) Rapid growth rate: Fast growth is a risk factor. (6) Insulin dysregulation: May influence bone and cartilage development. Extrinsic factors include: (1) High-concentrate diets: Excessive energy and imbalanced minerals. (2) Confinement: Limited exercise and pasture access. (3) Trauma: Neck injuries during handling or turnout. (4) Intense exercise: Repetitive stress on the cervical spine. (5) Nutritional deficiencies: Copper, zinc, and vitamin E deficiencies may impair bone health.

Clinical signs of CVSM vary depending on the severity and location of spinal cord compression. Common signs include: (1) Hindlimb ataxia: Incoordination, pelvic limb weakness, and a 'bunny-hopping' gait. (2) Forelimb involvement: In severe cases, forelimb ataxia and paresis may be present. (3) Proprioceptive deficits: Abnormal limb placement, crossing of limbs, and delayed response to knuckling. (4) Neck pain: Reluctance to flex or extend the neck, and muscle spasms. (5) Gait abnormalities: Short-strided, stiff gait, especially at the walk. (6) Worsening with exercise: Signs may be exacerbated by lunging or circling. (7) Muscle atrophy: In chronic cases, atrophy of the shoulder and hindquarter muscles. (8) Abnormal posture: Base-wide stance, swaying of the hindquarters. (9) In severe cases, recumbency and inability to rise. Neurological examination reveals UMN signs in the hindlimbs (spasticity, hyperreflexia) and GP deficits (delayed proprioceptive responses). Forelimb signs may be present if compression is at C6-T2. The severity can be graded using a scale from 0 (normal) to 5 (recumbent).

Differential diagnoses for CVSM include: (1) Equine Protozoal Myeloencephalitis (EPM): Caused by Sarcocystis neurona; presents with asymmetric ataxia, muscle atrophy, and cranial nerve deficits; diagnosis via CSF immunoblot or PCR. (2) Equine Herpesvirus Myeloencephalopathy (EHM): Caused by EHV-1; often associated with fever, respiratory signs, and multiple horses affected; diagnosis via PCR on nasal swabs or blood. (3) Cervical Vertebral Fracture: Acute onset, severe neck pain, and neurological deficits; diagnosis via radiography or scintigraphy. (4) Spinal Cord Trauma: History of trauma; radiography or MRI may reveal fracture or subluxation. (5) Neoplasia: Lymphoma or melanoma affecting the spinal cord; diagnosis via imaging and biopsy. (6) Abscess or Osteomyelitis: Vertebral body infection; may have fever and neck pain; diagnosis via radiography, ultrasound, or culture. (7) Degenerative Myelopathy: Older horses, progressive ataxia; diagnosis via exclusion and histopathology. (8) Cerebellar Abiotrophy: Young horses, intention tremors, and hypermetria; diagnosis via MRI or histopathology. (9) Lead Poisoning: Ataxia, dysphagia, and laryngeal paralysis; diagnosis via blood lead levels. (10) Botulism: Flaccid paralysis, dysphagia, and muscle weakness; diagnosis via toxin detection in serum or feces.

The diagnostic approach for CVSM includes: (1) Signalment and history: Young, large-breed horse with progressive ataxia. (2) Complete physical and neurological examination: Assess gait, proprioception, cranial nerves, and spinal reflexes. (3) Cervical radiography: Lateral and oblique views to evaluate vertebral canal diameter, articular process hypertrophy, and malformation. Myelography (contrast radiography) is often required to confirm compression. (4) Cerebrospinal fluid (CSF) analysis: To rule out inflammatory or infectious causes; may show elevated protein or nucleated cell count. (5) Advanced imaging: Computed tomography (CT) or magnetic resonance imaging (MRI) provides detailed assessment of spinal cord compression and soft tissue changes. (6) Electromyography (EMG): May reveal denervation in chronic cases. (7) Genetic testing: Research-based, not yet commercially available. (8) Response to treatment: In some cases, a trial of anti-inflammatory therapy may help differentiate from inflammatory conditions.

Laboratory findings in CVSM are often unremarkable. Complete blood count (CBC) and serum biochemistry are usually within normal limits. CSF analysis may show mild elevations in protein (50-100 mg/dL) and nucleated cell count (5-10 cells/µL), but these are nonspecific. In cases with concurrent osteochondrosis, serum markers of bone metabolism (e.g., osteocalcin, bone-specific alkaline phosphatase) may be altered. Genetic testing for markers associated with CVSM is under investigation. In cases with suspected nutritional imbalances, serum copper, zinc, and vitamin E levels may be assessed.

Imaging is crucial for diagnosis. Cervical radiography: Lateral projections may reveal vertebral canal stenosis (sagittal diameter < 2.0 cm in the cranial cervical region), articular process hypertrophy, and malformed vertebrae. Myelography: Intrathecal contrast injection demonstrates spinal cord compression, often at C3-C4 or C5-C6. CT: Provides cross-sectional images, allowing precise measurement of vertebral canal dimensions and identification of osseous compression. MRI: Offers superior soft tissue contrast, revealing spinal cord compression, edema, and gliosis. Scintigraphy: May show increased uptake in areas of active bone remodeling, but is nonspecific. Ultrasonography: Not typically used for cervical spine, but may be used to assess articular processes in some cases.

CSF cytology is often normal or shows mild mononuclear pleocytosis. Histopathology of the spinal cord reveals Wallerian degeneration, demyelination, and axonal loss in the white matter, particularly in the dorsolateral and ventromedial funiculi. In chronic cases, gliosis and fibrosis may be present. Articular process lesions show osteochondrosis, cartilage degeneration, and subchondral bone sclerosis. Necropsy findings include vertebral canal stenosis, articular process hypertrophy, and spinal cord compression.

Treatment of CVSM depends on the severity and type. Medical management includes: (1) Rest and confinement: To reduce biomechanical stress on the cervical spine. (2) Anti-inflammatory drugs: Non-steroidal anti-inflammatory drugs (NSAIDs) such as flunixin meglumine (1.1 mg/kg IV q12h) or phenylbutazone (2.2-4.4 mg/kg PO q12h) may reduce pain and inflammation. (3) Corticosteroids: Dexamethasone (0.05-0.1 mg/kg IV q24h) may be used for acute exacerbations, but long-term use is discouraged. (4) Nutritional management: Balanced diet with appropriate minerals and vitamins, avoiding excessive energy. (5) Physical therapy: Controlled exercise and physiotherapy may help maintain muscle strength. Surgical treatment: (1) Ventral slot decompression: For Type I-A malformation, involves removing the floor of the vertebral canal to relieve compression. (2) Dorsal laminectomy: For Type II instability, involves removing the dorsal lamina to decompress the spinal cord. (3) Vertebral stabilization: Fusion of affected vertebrae using screws or plates. Surgical success rates vary, with 50-70% of horses improving, but return to athletic function is limited. Prognosis is guarded to poor for severe cases.

The prognosis for CVSM is variable. For horses with mild signs, medical management may allow some improvement, but many progress. Surgical treatment offers a better chance for improvement, with 60-80% of horses showing neurological improvement, but only 20-40% return to athletic function. Negative prognostic indicators include: severe ataxia at presentation, long duration of signs, multiple sites of compression, and lack of response to treatment. Euthanasia is often elected in severe cases due to poor quality of life.

Follow-up care includes: (1) Serial neurological examinations every 4-6 weeks to assess progression. (2) Repeat imaging (radiography or CT) if clinical signs worsen. (3) Gradual return to exercise: Start with hand-walking, then lunging, and slowly increase intensity over 6-12 months. (4) Nutritional counseling: Ensure balanced diet to support bone health. (5) Regular farriery: Maintain hoof balance to prevent gait abnormalities. (6) Monitor for complications: Such as respiratory infections due to recumbency or surgical site infections.

Pearls: (1) Always perform a thorough neurological examination in any horse with gait abnormalities. (2) Cervical radiographs should be taken in young, large-breed horses with progressive ataxia. (3) Myelography is essential for confirming compression. (4) Early diagnosis and treatment may improve outcomes. (5) Consider genetic counseling for breeding animals. Pitfalls: (1) Misdiagnosing as EPM or EHM without imaging. (2) Delaying advanced imaging, leading to progression. (3) Overlooking concurrent conditions such as cervical arthritis. (4) Using corticosteroids without addressing underlying biomechanical issues. (5) Recommending surgery without proper case selection.

Medical management protocols include: (1) Flunixin meglumine: 1.1 mg/kg IV q12h for 3-5 days, then as needed. (2) Phenylbutazone: 2.2-4.4 mg/kg PO q12h for 5-7 days, then taper. (3) Dexamethasone: 0.05-0.1 mg/kg IV q24h for 3 days, then taper. (4) Gabapentin: 5-10 mg/kg PO q8h for neuropathic pain (off-label). (5) Vitamin E: 5000 IU/day PO for antioxidant support. (6) Balanced mineral supplementation: Ensure adequate copper, zinc, and calcium. Surgical protocols: (1) Perioperative antibiotics: Penicillin G (22,000 IU/kg IV q6h) and gentamicin (6.6 mg/kg IV q24h) for 24 hours. (2) Postoperative NSAIDs: Flunixin meglumine 1.1 mg/kg IV q12h for 3 days. (3) Postoperative rest: Stall rest for 4-6 weeks, then controlled exercise.

Landmark studies include: (1) A retrospective study by Reed et al. (1985) describing clinical signs and diagnostic findings in 100 horses with CVSM. (2) A study by Grant et al. (1985) evaluating surgical outcomes of ventral slot decompression, showing 60% improvement. (3) A study by Moore et al. (1994) comparing medical vs. surgical treatment, finding better outcomes with surgery. (4) A consensus statement by the ACVIM (2016) on diagnosis and treatment of CVSM. (5) A study by Levine et al. (2010) on genetic markers associated with CVSM. (6) A meta-analysis by Nout et al. (2015) on prognostic indicators, identifying severity of ataxia and duration of signs as negative predictors. These studies support the use of advanced imaging for diagnosis and surgical intervention for moderate to severe cases.